The Rebound Effect: What Research Shows
Multiple studies have examined what happens to body weight after GLP-1 medications are discontinued. The findings are consistent and sobering. In the STEP 1 extension trial, participants who stopped semaglutide after 68 weeks regained approximately two-thirds of their lost weight within one year of stopping. Similar patterns have been observed with liraglutide and tirzepatide.
Why Weight Returns
The return of weight after stopping GLP-1 is not a personal failure — it is a physiological consequence of removing the drug. GLP-1 medications work by maintaining an artificial hormonal state of reduced appetite and improved metabolic signaling. When the medication is removed, appetite returns to its pre-medication level, hunger hormones rebound, and biological pressure toward the body's previous weight set point reasserts itself. This is why obesity medicine specialists increasingly view GLP-1 therapy as a long-term or lifelong treatment for many patients.
What Habits Make the Biggest Difference
Patients who maintain the most weight loss after stopping GLP-1 are those who built the strongest behavioral habits during treatment. The most protective habits are regular resistance training (which maintains elevated metabolism through preserved lean mass), consistently high protein intake (which maintains satiety and muscle), structured meal planning (which removes dependence on hunger cues as the primary eating trigger), and regular monitoring of body weight and food intake.
September 2026 Update: Stopping GLP-1 Raises Cardiovascular Risk
Washington University / BMJ Medicine — September 20, 2026: Researchers at Washington University School of Medicine in St. Louis tracked more than 333,000 U.S. veterans with type 2 diabetes for three years and found that stopping GLP-1 therapy for as little as six months was associated with a meaningful increase in the risk of major cardiovascular events — including heart attack, stroke, and death — compared with patients who continued treatment. After two years without GLP-1 therapy, cardiovascular risk was up to 22% higher than in those who stayed on the medication, largely wiping out the heart protection gained during treatment. Restarting therapy restored some protection but only partially, suggesting discontinuation leaves a lasting impact on cardiovascular health. The findings, published in BMJ Medicine, reinforce that for many patients GLP-1 therapy needs to be viewed as long-term — not just a short-term weight loss tool. Source: Washington University in St. Louis / BMJ Medicine, September 20, 2026.
Planning for Stopping
If you are considering or planning to stop your GLP-1 medication, discuss it with your healthcare provider in advance. A gradual dose reduction rather than abrupt cessation may reduce the speed of appetite return. Intensifying your focus on protein intake and resistance training in the months before stopping gives your body the best foundation for maintaining results.